Chronic myeloid leukemia presenting with extramedullary disease as massive ascites responding to imatinib mesylate.
Patients with chronic myeloid leukemia (CML) can develop extramedullary involvement during the course of the illness. This usually occurs during the accelerated phase or blast crisis. We describe a patient who presented with massive ascites probably due to mesenteric/peritoneal infiltration during chronic phase CML. There was an excellent response to imatinib with a complete cytogenetic response and total disappearance of ascites.
Aleem
Aamer
A
Department of Medicine, Hematology/Oncology Division, King Khalid University Hospital, Riyadh, Saudi Arabia. aameraleem@hotmail.com
Siddiqui
Neelam
N
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001201:Ascites / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology*; D001549:Benzamides; D001752:Blast Crisis / Q000235:genetics*; D020732:Cytogenetic Analysis; D016044:Fusion Proteins, bcr-abl / Q000235:genetics; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D012074:Remission Induction
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl